RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.51%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$791M
AUM Growth
+$791M
(-9.1%)
Cap. Flow
-$75.2M
Cap. Flow
% of AUM
-9.51%
Top 10 Holdings %
Top 10 Hldgs %
32.88%
Holding
105
New
11
Increased
29
Reduced
37
Closed
15
Top Buys
| 1 |
Danaher
DHR
|
$15.7M |
| 2 |
Eli Lilly
LLY
|
$12.6M |
| 3 |
Encompass Health
EHC
|
$12.1M |
| 4 |
Cardinal Health
CAH
|
$9.24M |
| 5 |
Neurocrine Biosciences
NBIX
|
$7.47M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$19.8M |
| 2 |
Oscar Health
OSCR
|
$15.2M |
| 3 |
Procept Biorobotics
PRCT
|
$14.9M |
| 4 |
UnitedHealth
UNH
|
$14.7M |
| 5 |
McKesson
MCK
|
$14.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Universal Health Services
UHS
$11.6B
| $4.71M | 0.6% |
+26,000
| New | +$4.71M |
|
52
Stryker
SYK
$150B
| $4.55M | 0.58% |
+11,500
| New | +$4.55M |
|
53
Thermo Fisher Scientific
TMO
$186B
| $4.52M | 0.57% |
11,140
-1,500
| -12% | -$608K |
|
54
Arcellx
ACLX
$3.85B
| $4.43M | 0.56% |
67,250
+23,750
| +55% | +$1.56M |
|
55
Edwards Lifesciences
EW
$47.8B
| $4.3M | 0.54% |
+55,000
| New | +$4.3M |
|
56
TG Therapeutics
TGTX
$4.65B
| $4.14M | 0.52% |
115,000
-62,500
| -35% | -$2.25M |
|
57
Nuvalent
NUVL
$5.52B
| $4.01M | 0.51% |
52,500
| – | – |
|
58
Inspire Medical Systems
INSP
$2.77B
| $3.96M | 0.5% |
30,500
+14,500
| +91% | +$1.88M |
|
59
BioNTech
BNTX
$24B
| $3.82M | 0.48% |
35,870
+120
| +0.3% | +$12.8K |
|
60
Cytokinetics
CYTK
$4.23B
| $3.44M | 0.44% |
104,250
| – | – |
|
61
Ultragenyx Pharmaceutical
RARE
$2.89B
| $3.39M | 0.43% |
93,100
+11,100
| +14% | +$404K |
|
62
Mirum Pharmaceuticals
MIRM
$3.71B
| $3.35M | 0.42% |
65,755
-8,000
| -11% | -$407K |
|
63
Structure Therapeutics
GPCR
$1.11B
| $2.8M | 0.35% |
135,100
+65,100
| +93% | +$1.35M |
|
64
RadNet
RDNT
$5.52B
| $2.62M | 0.33% |
+46,000
| New | +$2.62M |
|
65
Vericel Corp
VCEL
$1.83B
| $2.47M | 0.31% |
+58,000
| New | +$2.47M |
|
66
Repligen
RGEN
$6.88B
| $2.43M | 0.31% |
19,500
+15,000
| +333% | +$1.87M |
|
67
LivaNova
LIVN
$3.08B
| $2.39M | 0.3% |
+53,000
| New | +$2.39M |
|
68
Dianthus Therapeutics
DNTH
$759M
| $2.36M | 0.3% |
126,627
| – | – |
|
69
Viking Therapeutics
VKTX
$3.04B
| $2.25M | 0.28% |
85,000
-15,000
| -15% | -$398K |
|
70
MoonLake Immunotherapeutics
MLTX
$3.54B
| $2.12M | 0.27% |
45,000
| – | – |
|
71
Nurix Therapeutics
NRIX
$714M
| $2.11M | 0.27% |
185,000
-64,336
| -26% | -$733K |
|
72
Privia Health
PRVA
$2.83B
| $2.1M | 0.27% |
91,189
-7,000
| -7% | -$161K |
|
73
IQVIA
IQV
$32.4B
| $2.05M | 0.26% |
13,000
-9,000
| -41% | -$1.42M |
|
74
Krystal Biotech
KRYS
$4.27B
| $1.75M | 0.22% |
12,750
-5,000
| -28% | -$687K |
|
75
Summit Therapeutics
SMMT
$17.6B
| $1.66M | 0.21% |
+78,000
| New | +$1.66M |
|